Innate Pharma SA — FY2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing; the filing gives Q4 Lumoxiti sales but does not provide a full quarterly income statement or cash-flow statement. Financial statements are prepared under IFRS in euros.
Business context
Innate Pharma is a clinical-stage immuno-oncology biotechnology company whose income primarily comes from collaboration and licensing agreements, grants and French research tax credits. Its lead programs include partnered monalizumab and IPH5201, and wholly owned lacutamab and avdoralimab. In December 2020, the company decided to return Lumoxiti commercialization rights to AstraZeneca and refocus investment on research and development.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue and other income | €70.5 million | €85.8 million |
| Collaboration and licensing revenue | €56.2 million | €69.0 million |
| Government research financing | €13.6 million | €16.8 million |
| Net sales | €0.7 million | None reported |
| Research and development expenses | €58.6 million | €78.8 million |
| Selling, general and administrative expenses | €31.2 million | €25.8 million |
| Impairment of intangible assets | €43.5 million | None |
| Operating loss | €62.1 million | €27.1 million |
| Net loss | €64.0 million | €20.8 million |
| Operating cash flow | €(51.8) million | €34.9 million |
| Cash, cash equivalents and short-term investments | €151.6 million | €218.9 million |
| Cash, cash equivalents, short-term investments and non-current financial assets | €190.6 million | €255.9 million |
| Total assets | €307.4 million | €401.4 million |
| Shareholders’ equity | €156.0 million | €217.4 million |
Margins are not presented as a meaningful standalone measure for this development-stage business. The filing reports total financial debt and defined-benefit obligations of €23.3 million at year-end 2020. Separately, financial liabilities were €19.1 million, including €13.7 million remaining on the building loan. The company also had €4.2 million in defined-benefit obligations.
Material changes and unusual items
- Revenue and other income fell 17.9% year over year. Collaboration and licensing revenue declined 18.6%, chiefly reflecting lower recognized revenue from monalizumab and IPH5201; the €7.0 million Sanofi milestone for advancing IPH6101 partly offset the decline.
- R&D expense fell 25.7%, mainly due to lower direct clinical and preclinical spending, including lower Lumoxiti, preclinical-program and monalizumab costs. SG&A rose 21.1%, reflecting Lumoxiti commercialization and U.S. operations during the transition.
- The €43.5 million impairment fully wrote down Lumoxiti rights after the decision to return them to AstraZeneca. The company recognized €0.7 million of Lumoxiti sales in Q4 after the U.S. transition period ended September 30, 2020.
- Net financial results shifted from €6.3 million income in 2019 to a €1.9 million loss in 2020, mainly due to lower gains on financial assets and foreign-exchange losses.
- Operating cash flow was negative €51.8 million, compared with positive €34.9 million in 2019. The filing attributes the change in part to the timing of collaboration receipts and higher operating cash outflows. Investing cash flow was negative €13.4 million and financing cash flow negative €1.2 million.
- Cash, cash equivalents and short-term investments decreased by €67.3 million during 2020. The company received a €50 million AstraZeneca milestone following the first patient dosed in the monalizumab Phase III INTERLINK-1 trial; a further €50 million is conditional on interim clinical activity.
Outlook, risks and contingencies
- Management stated that available cash, investments and expected operating cash flow should fund operations for the next 12 months. It also expects to need additional financing to complete development and potential commercialization of internally developed candidates. Future funding may depend on partner milestones, collaborations, equity or debt financing, grants and tax credits.
- Key development plans include continued lacutamab trials, AstraZeneca’s Phase III INTERLINK-1 study of monalizumab, and development of partnered and proprietary pipeline programs. Management cautions that clinical outcomes, approvals and milestone receipts are uncertain.
- The Lumoxiti transition agreement with AstraZeneca was not finalized as of the report date. If no agreement is reached, Innate estimated it could incur up to $12.8 million in manufacturing and distribution costs; a prolonged transition could also increase patient-support and distribution costs.
- COVID-19 created risks to trial enrollment, site participation, data quality, supply and milestone timing. Management identified clinical-trial disruption as the most immediate pandemic-related risk.
- The company relies on third parties for manufacturing, clinical research and key materials, and depends substantially on AstraZeneca, Sanofi and other collaborators. Clinical failure, regulatory delays, partner decisions, competition and funding availability are material risks.
- Management identified a material weakness in internal control over financial reporting, involving journal entries, complex transactions and revenue calculations, including monalizumab revenue. A material revenue error was corrected before the financial statements were published, but disclosure controls were deemed ineffective at year-end. Remediation was ongoing.
- The filing reports no material legal proceedings judged likely to adversely affect the business. It also discloses a class action related to monalizumab statements that was voluntarily dismissed on March 29, 2021.
Most important facts for investors to verify
- Progress and interim results for INTERLINK-1 and lacutamab’s TELLOMAK trial, including the timing and substance of anticipated data releases.
- Completion, terms and costs of the Lumoxiti rights transition, and whether the potential $12.8 million exposure is avoided or changes.
- Cash runway assumptions and the timing, amount and conditions of future partner milestones or external financing.
- Whether the company remediates the material weakness and improves review controls over collaboration revenue and unusual transactions.
- Future clinical-trial enrollment, manufacturing reliability and COVID-19-related disruption across company- and partner-sponsored programs.
- Potential dilution from outstanding share-based awards and the accuracy of share-count disclosures: the filing reports 78,986,490 ordinary shares outstanding, while the consolidated equity note also includes preferred shares.